Epsilon Healthcare has received updated GMP compliance certificates for its Southport facility covering domestic, EU and UK mutual recognition pathways.
The firm said the approvals, issued by the TGA and valid until June 16, 2026, underpin its plan to expand its contract manufacturing and international sales pipeline from the site.
Chief executive Peter Giannopoulos said the certification was “a terrific endorsement of our robust quality systems and the excellent work performed by our Southport team.”
“We are positioned to accelerate client onboarding and exports into regulated markets, while continuing to deliver a high-quality range of products to our clients for Australian patients,” he added.
The company is attempting to exit administration, with Giannopoulos labelling 2025 as a “relaunch”.
Althea Group Holdings
Althea Group Holdings (AGH) secured $2.6 million through a share placement priced at $0.018 per share.
The funds will support growth initiatives, customer development and selected capital expenditure, with the company describing its strategic reset as complete and now focused solely on THC beverages through its Canadian subsidiary, Peak Processing Solutions.
Interim chief executive Barry Katzman said the raise came at “the perfect time to drive growth and strengthen financial outcomes at Peak,” adding that strong shareholder support was encouraging, as the company pursues expansion in Canada and the US.
AGH exited Australia this year, after selling its pharmaceutical assets to Tasmanian Botanics in a deal worth $1million.
Zelira Therapeutics
Zelira received USD$150,000 (A$224,000) in unsecured loan notes from managing director Oludare Odumosu and non-executive director Donna Gentile O’Donnell.
The company said the money would be used for general working capital.
The board – excluding Odumosu and O’Donnell – noted the terms were favourable given current market conditions.
Bioxyne
Brisbane-based manufacturer Bioxyne has received orders to export more than A$5 million worth of medicinal cannabis flower to Germany.
It follows a commercial agreement struck in June to supply a minimum of 1,600kg of flower to Farmakem during FY26m – a deal valued at $5.6m – to be distributed in Germany by Adrex Pharmaceuticals
The order will see the bulk of that, 1,550kg, exported towards the end of September or early October.
With its German partners expected to buy more product in November, January, March and May, Bioxyne said total orders are likely to exceed the volumes contracted in June.